Ilgın Yıldırım ŞİMŞİR, Gökçen ÜNAL KOCABAŞ, Çığır Biray AVCI, Füsun SAYGILI

Zoledronik Asidin BCPAP Tiroid Papiller Karsinomu Hücre Hattında Etkiler

GİRİŞ ve AMAÇ: Türkiye’de sıklığı %3.7 olarak tanımlanan tiroid kanserleri en sık görülen endokrin neoplazilerdir. Mitojen aktive protein kinaz (MAPK) yolağındaki proteinleri kodlayan genlerdeki mutasyon ve yeniden düzenlemeler, diferansiye tiroid kanseri gelişimi ve ilerlemesi için giderek daha fazla önem kazanmaktadırlar. Bifosfonatlar invitro olarak; tümör hücre proliferasyonunu azaltır, hücre viabilitesini azaltır, tümör hücre apopitosisini uyarır, hücre adezyonu inhibisyonu yapar, anjiyogenezde inhibisyon ve metastatik potansiyelde azalma yaparlar. Çalışmamızda zoledronik asit monohidratın tiroid papiller karsinomu hücre hattında sitotoksisite ve apoptozis üzerine etkileri araştırılmıştır. YÖNTEM ve GEREÇLER: İnsan kökenli bir papiller tiroid karsinomu hücre hattında (BCPAP) bifosfonat olarak zoledronik asid monohidratın 10-100 µM şeklinde artan dozları kullanıldı. BULGULAR: BCPAP hücre hattında zoledronik asid monohidratın IC50 değeri 1. deneyde 48. saatte 55 µM olarak saptandı. Ancak 2, 3 ve 4. deneylerde sonuç alınamadı. Bu nedenle apopitozis deneyleri kurulmadı. TARTIŞMA ve SONUÇ: Zoledronik asit, çalıştığımız doz aralığında tiroid papiller karsinomu hücre hattında etkisiz bulunmuştur..

Effects of Zoledronic Acid in BCPAP Thyroid Papillary Carcinoma Cell Line

INTRODUCTION: Thyroid cancer is the most common endocrine neoplasm with an incidence of 3.7% in Turkey. Mutations and re-arrangements in genes encoding proteins of the the mitogen-activated protein kinase (MAPK) pathway for the development and progression of differentiated thyroid cancer, gain more and more importance. Bisphosphonates decrease tumor cell proliferation, reduce cell viability, stimulate apopitosis in tumor cell, inhibit cell adhesion and angiogenesis, and decrease metastatic potential in vitro. In our study, the effects of zoledronic acid monohydrate on cytotoxicity and apoptosis in thyroid papillary carcinoma cell line were investigated. METHODS: Zoledronic acid monohydrate with increasing doses of 10 to 100 μM was used on a papillary thyroid carcinoma cell line of human origin named BCPAP. RESULTS: IC50 value with zoledronic acid monohydrate was found in first experiment at 48th hour to be 55 μM, but 2nd, 3rd and 4th experiments were failed. Therefore, apoptosis assays were not to be established. DISCUSSION and CONCLUSION: Zoledronic acid was found to be ineffective in the thyroid papillary carcinoma cell line at the dose range we were working with

PDF

___

1. Tanriover O, Comunoglu N, Eren B, Comunoglu C, Turkmen N, Dogan M, et al. Occult papillary thyroid carcinoma: prevalence at autopsy in Turkish people. Eur J Cancer Prev 2011 Jul; 20(4): 308-12.
2. Kabalak T. Tiroid El Kitabı. İzmir: Güneş Tıp Kitapevi; 2012. 1. Cilt
3. Werk EE Jr, Vernon BM, Gonzalez JJ, Ungaro PC, McCoy RC. Cancer in thyroid nodules. A community hospital survey. Arch Intern Med 1984; 144(3): 474-6.
4. Belfiore A, Giuffrida D, La Rosa GL, Ippolito O, Russo G, Fiumara A, et al. High frequency of cancer in cold thyroid nodules occurring at young age. Acta Endocrinol (Copenh) 1989; 121(2): 197-202.
5. Hegedüs L. Clinical practice. The thyroid nodule. N Engl J Med 2004; 351(17): 1764-71.
6. Lin JD, Chao TC, Huang BY, Chen ST, Chang HY, Hsueh C. Thyroid cancer in the thyroid nodules evaluated by ultrasonography and fineneedle aspiration cytology. Thyroid 2005; 15(7): 708-17.
7. Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. J Cell Sci 2005 March 1; 118(Pt 5): 843-6.
8. Proye CA, Dromer DH, Carnaille BM, Gontier AJ, Goropoulos A, Carpentier P, et al. Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine? World J Surg 1992; 16(4): 640-5.
9. Pilli T, Prasad KV, Jayarama S, Pacini F, Prabhakar BS. Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer. Thyroid 2009 Dec; 19(12): 1333-42.
10.Puppin C, D'Aurizio F, D'Elia AV, Cesaratto L, Tell G, Russo D, et al. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. Endocrinology 2005 Sep; 146(9): 3967-74.
11.Wang W, Le W, Cho DY, Hwang PH, Upadhyay D. Novel effects of statins in enhancing efficacy of chemotherapy in vitro in nasopharyngeal carcinoma. Int Forum Allergy Rhinol 2011 Jul-Aug; 1(4): 284-9.
12.Riganti C, Pinto H, Bolli E, Belisario DC, Calogero RA, Bosia A, et al. Atorvastatin modulates anti-proliferative and proproliferative signals in Her2/neu-positive mammary cancer. Biochem Pharmacol 2011; 82(9): 1079-89.
13.Zhong WB, Wang CY, Chang TC, Lee WS. Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology 2003; 144(9): 3852-9.
14.Sánchez CA, Rodríguez E, Varela E, Zapata E, 15.Páez A, Massó FA, et al. Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress. Cancer Invest 2008; 26(7): 698-707.
16.Cohen SM, Mukerji R, Timmermann BN, Samadi AK, Cohen MS. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers. Am J Surg 2012 Dec; 204(6): 895-900.
17.Bulotta S, Corradino R, Celano M, Maiuolo J, D'Agostino M, Oliverio M, et al. Antioxidant and antigrowth action of peracetylated oleuropein in thyroid cancer cells. J Mol Endocrinol 2013 Jun 29; 51(1): 181-9.